HGH Fragment 176-191
250–500 mcg · Daily
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 3 cited sources
Evidence
- Human Studies
- 3
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Unknown — human evidence for the fat-loss claim specifically is thin, and long-term safety data is essentially absent
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
HGH Fragment 176-191 is a synthetic fragment of the C-terminal region of growth hormone that, in animal studies, retains GH's fat-metabolizing effect without significantly affecting blood sugar, IGF-1, or tissue growth the way full-length GH does. Human data supporting this fat-loss-specific effect is far thinner than the animal literature.
Common Protocols
- 250–500 mcg subcutaneous daily, often on an empty stomach
- Sometimes injected near targeted fat deposits based on unproven "spot reduction" theory
Side Effects
- Injection site irritation
- Limited systematic human safety data
Interactions
- No formal interaction data exists
Practical Details
- Cost
- $$
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Key Studies & Reviews
- Heffernan MA et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with hGH or a modified C-terminal fragment. Int J Obes Relat Metab Disord. PMID 11673763.
- Heffernan M et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese mice. Endocrinology. PMID 11713213.
- Dominikowski A et al. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Front Endocrinol. PMID 42395176.
Search the Research
HGH Fragment 176-191 FAQ
What is the typical HGH Fragment 176-191 dosage?
Commonly reported protocols: 250–500 mcg subcutaneous daily, often on an empty stomach; Sometimes injected near targeted fat deposits based on unproven "spot reduction" theory. Our reference entry uses 250–500 mcg, Daily. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of HGH Fragment 176-191?
Reported side effects include: Injection site irritation; Limited systematic human safety data.
Is HGH Fragment 176-191 FDA approved?
HGH Fragment 176-191 is not FDA approved for human use and is generally sold as a research chemical, so purity and dosing are not regulated.
How much research is there on HGH Fragment 176-191?
Our evidence profile counts roughly 3 human and 20 animal studies, with low overall confidence. Long-term safety: Unknown — human evidence for the fat-loss claim specifically is thin, and long-term safety data is essentially absent.
Does HGH Fragment 176-191 interact with other drugs or supplements?
No formal interaction data exists.
How do I reconstitute HGH Fragment 176-191?
A common setup is a 5 mg vial mixed with 2 mL of bacteriostatic water, which puts a 250–500 mcg dose at about 5 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution.
Related compounds
Fat-loss-targeted fragment of growth hormone; does not raise GH itself